Dehlin, M., Jacobsson, L. & Roddy, E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat. Rev. Rheumatol. 16, 380–390 (2020).
Cabău, G., Crișan, T. O., Klück, V., Popp, R. A. & Joosten, L. A. B. Urate-induced immune programming: consequences for gouty arthritis and hyperuricemia. Immunol. Rev. 294, 92–105 (2019).
Choi, H. K., McCormick, N. & Yokose, C. Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care. Nat. Rev. Rheumatol. 18, 97–111 (2021).
Yang, L. et al. Biomimetic polysaccharide-cloaked lipidic nanovesicles/microassemblies for improving the enzymatic activity and prolonging the action time for hyperuricemia treatment. Nanoscale 12, 15222–15235 (2020).
Sands, E. et al. Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against PEGylated uricase in patients with hyperuricemia. Nat. Commun. 13, 272 (2022).
Chen, R. et al. M2 macrophage hybrid membrane-camouflaged targeted biomimetic nanosomes to reprogram inflammatory microenvironment for enhanced enzyme-thermo-immunotherapy. Adv. Mater. 35, e2304123 (2023).
Qaseem, A., Harris, R. P. & Forciea, M. A. Management of acute and recurrent gout: a clinical practice guideline from the American college of physicians. Ann. Intern. Med. 166, 58–68 (2016).
van Durme, C. M. P. G. et al. Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Sys. Rev. 2021, CD010120 (2021).
Gao, Z.-S. et al. Berberine-loaded M2 macrophage-derived exosomes for spinal cord injury therapy. Acta Biomater. 126, 211–223 (2021).
Hooftman, A. et al. Macrophage fumarate hydratase restrains mtRNA-mediated interferon production. Nature 615, 490–498 (2023).
Yang, R. et al. Exosomes derived from M2b macrophages attenuate DSS-induced colitis. Front. Immunol. 10, 2346 (2019).
Li, H. et al. M2-type exosomes nanoparticles for rheumatoid arthritis therapy via macrophage re-polarization. J. Control. Release 341, 16–30 (2022).
Kalluri, R. & LeBleu, V. S. The biology, function, and biomedical applications of exosomes. Science 367, eaau6977 (2020).
Zhang, Y. et al. Macrophage membrane biomimetic drug delivery system: for inflammation targeted therapy. J. Drug Target. 31, 229–242 (2023).
Thamphiwatana, S. et al. Macrophage-like nanoparticles concurrently absorbing endotoxins and proinflammatory cytokines for sepsis management. Proc. Natl Acad. Sci. USA 114, 11488–11493 (2017).
Sun, T. et al. Amelioration of ulcerative colitis via inflammatory regulation by macrophage-biomimetic nanomedicine. Theranostics 10, 10106–10119 (2020).
Pedone, D., Moglianetti, M., De Luca, E., Bardi, G. & Pompa, P. P. Platinum nanoparticles in nanobiomedicine. Chem. Soc. Rev. 46, 4951–4975 (2017).
Lin, A. et al. Self-cascade uricase/catalase mimics alleviate acute gout. Nano Lett. 22, 508–516 (2021).
Zhou, D. et al. Orally administered platinum nanomarkers for urinary monitoring of inflammatory bowel disease. ACS Nano 16, 18503–18514 (2022).
He, S.-B. et al. Sodium alginate modified platinum nanozymes with highly efficient and robust oxidase-like activity for antioxidant capacity and analysis of proanthocyanidins. Front. Chem. 8, 654 (2020).
Yu, J. et al. Synergistic enhancement of immunological responses triggered by hyperthermia sensitive Pt NPs via NIR laser to inhibit cancer relapse and metastasis. Bioact. Mater. 7, 389–400 (2022).
Yu, H. et al. Biomimetic hybrid membrane-coated xuetongsu assisted with laser irradiation for efficient rheumatoid arthritis therapy. ACS Nano 16, 502–521 (2021).
Zhang, M. et al. Advanced application of stimuli-responsive drug delivery system for inflammatory arthritis treatment. Mater. Today Bio 14, 100223 (2022).
Dong, Y., Cao, W. & Cao, J. Treatment of rheumatoid arthritis by phototherapy: advances and perspectives. Nanoscale 13, 14591–14608 (2021).
Bonkowski, M. S. & Sinclair, D. A. Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds. Nat. Rev. Mol. Cell Biol. 17, 679–690 (2016).
Singh, A. P. et al. Health benefits of resveratrol: evidence from clinical studies. Med. Res. Rev. 39, 1851–1891 (2019).
Fan, W., Chen, S., Wu, X., Zhu, J. & Li, J. Resveratrol relieves gouty arthritis by promoting mitophagy to inhibit activation of NLRP3 inflammasomes. J. Inflamm. Res. 14, 3523–3536 (2021).
Schlesinger, N., Padnick-Silver, L. & LaMoreaux, B. Enhancing the response rate to recombinant uricases in patients with gout. BioDrugs 36, 95–103 (2022).
Bao, Y.-W., Hua, X.-W., Chen, X. & Wu, F.-G. Platinum-doped carbon nanoparticles inhibit cancer cell migration under mild laser irradiation: multi-organelle-targeted photothermal therapy. Biomaterials 183, 30–42 (2018).
Wang, D. et al. Erythrocyte–cancer hybrid membrane camouflaged hollow copper sulfide nanoparticles for prolonged circulation life and homotypic-targeting photothermal/chemotherapy of melanoma. ACS Nano 12, 5241–5252 (2018).
Yuan, D. et al. Macrophage exosomes as natural nanocarriers for protein delivery to inflamed brain. Biomaterials 142, 1–12 (2017).
Cai, R. & Chen, C. The crown and the scepter: roles of the protein corona in nanomedicine. Adv. Mater. 31, e1805740 (2018).
Sies, H. & Jones, D. P. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat. Rev. Mol. Cell Biol. 21, 363–383 (2020).
Tardito, S. et al. Macrophage M1/M2 polarization and rheumatoid arthritis: a systematic review. Autoimmun. Rev. 18, 102397 (2019).
Liu, C. et al. Microfluidic sonication to assemble exosome membrane-coated nanoparticles for immune evasion-mediated targeting. Nano Lett. 19, 7836–7844 (2019).
Polanco, J. C., Hand, G. R., Briner, A., Li, C. & Götz, J. Exosomes induce endolysosomal permeabilization as a gateway by which exosomal tau seeds escape into the cytosol. Acta Neuropathol. 141, 235–256 (2021).
Li, Q. et al. Targeted immunomodulation therapy for cardiac repair by platelet membrane engineering extracellular vesicles via hitching peripheral monocytes. Biomaterials 284, 121529 (2022).
Keller, M. D. et al. Decoy exosomes provide protection against bacterial toxins. Nature 579, 260–264 (2020).
Xu, E., Saltzman, W. M. & Piotrowski-Daspit, A. S. Escaping the endosome: assessing cellular trafficking mechanisms of non-viral vehicles. J. Control. Release 335, 465–480 (2021).
Qiu, C. et al. Advanced strategies for overcoming endosomal/lysosomal barrier in nanodrug delivery. Research 6, 0148 (2023).
Zhang, J. et al. Mitochondrial-targeted delivery of polyphenol-mediated antioxidases complexes against pyroptosis and inflammatory diseases. Adv. Mater. 35, e2208571 (2023).
Wang, Y. et al. Resveratrol mediates mechanical allodynia through modulating inflammatory response via the TREM2-autophagy axis in SNI rat model. J. Neuroinflammation 17, 311 (2020).
Tang, Q. et al. Genetically engineering cell membrane-coated BTO nanoparticles for MMP2-activated piezocatalysis-immunotherapy. Adv. Mater. 35, e2300964 (2023).
Wei, Z., Oh, J., Flavell, R. A. & Crawford, J. M. LACC1 bridges NOS2 and polyamine metabolism in inflammatory macrophages. Nature 609, 348–353 (2022).
Zhou, B., Lu, J. G., Siddu, A., Wernig, M. & Südhof, T. C. Synaptogenic effect of APP-Swedish mutation in familial Alzheimer’s disease. Sci. Transl. Med. 14, eabn9380 (2022).
Tang, X. et al. Long noncoding RNA LEENE promotes angiogenesis and ischemic recovery in diabetes models. J. Clin. Invest. 133, e161759 (2023).
Holick, M. F. et al. Genomic or non-genomic? A question about the pleiotropic roles of vitamin D in inflammatory-based diseases. Nutrients 15, 767 (2023).
Wang, K. et al. Structural mechanism for GSDMD targeting by autoprocessed caspases in pyroptosis. Cell 180, 941–955.e920 (2020).
Ference, B. A. et al. Mendelian randomization study of ACLY and cardiovascular disease. N. Engl. J. Med. 380, 1033–1042 (2019).
Newman-Tancredi, A., Depoortère, R. Y., Kleven, M. S., Kołaczkowski, M. & Zimmer, L. Translating biased agonists from molecules to medications: serotonin 5-HT1A receptor functional selectivity for CNS disorders. Pharmacol. Ther. 229, 107937 (2022).
Wedell-Neergaard, A.-S. et al. Exercise-induced changes in visceral adipose tissue mass are regulated by IL-6 signaling: a randomized controlled trial. Cell Metab. 29, 844–855.e843 (2019).
Nakka, K. et al. JMJD3 activated hyaluronan synthesis drives muscle regeneration in an inflammatory environment. Science 377, 666–669 (2022).
Muendlein, H. I. et al. Neutrophils and macrophages drive TNF-induced lethality via TRIF/CD14-mediated responses. Sci. Immunol. 7, eadd0665 (2022).
Sobolewski, C. et al. S100A11/ANXA2 belongs to a tumour suppressor/oncogene network deregulated early with steatosis and involved in inflammation and hepatocellular carcinoma development. Gut 69, 1841–1854 (2020).
Yu, Z. et al. TRIM41 is required to innate antiviral response by polyubiquitinating BCL10 and recruiting NEMO. Signal Transduct. Target. Ther. 6, 90 (2021).
Luo, L. et al. Rab8a interacts directly with PI3Kγ to modulate TLR4-driven PI3K and mTOR signalling. Nat. Commun. 5, 4407 (2014).
Andonian, B. J. et al. Altered skeletal muscle metabolic pathways, age, systemic inflammation, and low cardiorespiratory fitness associate with improvements in disease activity following high-intensity interval training in persons with rheumatoid arthritis. Arthritis Res. Ther. 23, 187 (2021).
Pezone, A. et al. Inflammation and DNA damage: cause, effect or both. Nat. Rev. Rheumatol. 19, 200–211 (2023).
Zhao, Y., Simon, M., Seluanov, A. & Gorbunova, V. DNA damage and repair in age-related inflammation. Nat. Rev. Immunol. 23, 75–89 (2022).
Sun, L. et al. Clodronate-loaded liposomal and fibroblast-derived exosomal hybrid system for enhanced drug delivery to pulmonary fibrosis. Biomaterials 271, 120761 (2021).
Hu, S. et al. Platelet membrane and stem cell exosome hybrids enhance cellular uptake and targeting to heart injury. Nano Today 39, 101210 (2021).
Liang, Y. et al. Chondrocyte-specific genomic editing enabled by hybrid exosomes for osteoarthritis treatment. Theranostics 12, 4866–4878 (2022).
Mondal, J. et al. Hybrid exosomes, exosome-like nanovesicles and engineered exosomes for therapeutic applications. J. Control. Release 353, 1127–1149 (2023).
Lin, Y. et al. Exosome–liposome hybrid nanoparticles deliver CRISPR/Cas9 system in MSCs. Adv. Sci. 5, 1700611 (2018).
Schlesinger, N., Pérez-Ruiz, F. & Lioté, F. Mechanisms and rationale for uricase use in patients with gout. Nat. Rev. Rheumatol. 19, 640–649 (2023).
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.nature.com/articles/s41565-024-01715-0